Thought Leadership

Our leading subject matter experts share their insightful analysis and points of view to help you stay abreast of industry trends

MMIT Thought Leadership

Understanding Access Barriers in 2024 and Beyond

By Dinesh Kabaleeswaran and Jen Klarer

Navigating the landscape of patient access in the pharma industry has become increasingly complex, extending far beyond traditional channels. The challenges are multifaceted, influenced by evolving policies, innovative payer strategies, and shifts in provider dynamics.

Recent market research conducted by MMIT and The Dedham Group, encompassing insights from more than 300 industry stakeholders, sheds light on the critical barriers to patient access that are top of mind for pharma executives.

© 2024 MMIT

Solving Access Barriers in Biomarker Testing: 5 Tips for Manufacturers

By Hannah Baxter, Jen Klarer and Carolyn Zele

Despite the rapid evolution of personalized medicine, access to genetic testing and next-generation sequencing (NGS) is a challenge—due in no small part to coverage confusion. Physicians struggle to navigate poorly defined testing coverage policies and a fragmentated payer and vendor ecosystem, resulting in delayed care for patients requiring precision therapies.

What’s New in the Hypertension Market?

By Jacquie Eckrote

The hypertension market is no stranger to new entrants, with therapies ranging from calcium channel blockers and angiotensin II receptor blockers (ARBs) to angiotensin-converting enzyme (ACE) inhibitors and beta blockers. As a mature market, generics are widely available, and many of the more recently approved therapies are combinations of existing agents or different formulations of FDA-approved treatments.

0 Comments Industry Trends
© 2024 MMIT

Focusing on Social Determinants of Health: How to Make an Impact

By Adelaide Blanchard

Consideration of patients’ social determinants of health (SDoH) has been a facet of healthcare delivery in the United States for decades. The CDC defines SDoH as the nonmedical factors that influence a patient’s health outcomes, such as access to care services and medication, housing and food stability, education levels, and employment.

0 Comments Industry Trends
© 2024 MMIT

Changing Payer Management Dynamics at Play in Oncology

By Jory Fleischauer, Pharm.D

When it comes to the degree of payer management within a therapeutic area, pharma companies are becoming the victim of their own successes. One prime example is the rapid growth of competitive therapies across tumor types, pharmacological classes, and mechanisms of action in oncology. Payers have responded to the launch of more innovative and highly effective therapies with increased utilization management restrictions to balance the cost and quality of care.

© 2024 MMIT

Cordavis Could Benefit U.S. Biosimilars Market

By Julia Scanlan

It has now been over a year since the first Humira biosimilar, Amgen's Amjevita, entered the U.S. market. Eight additional adalimumab biosimilars followed suit, offering lower-cost alternatives to AbbVie’s blockbuster drug via a variety of dual-pricing and discounting strategies.

© 2024 MMIT

Tips for Successful Market Entry for Small and Mid-Size Pharma Companies

By Ryan Witherington and Olga Yaremchuk

In our collective experience working with dozens of clients, we’ve found that smaller pharma companies and biotechs wrestle with many common challenges, regardless of their therapeutic area. From limited budgets to a late start on market access activities, we see the same roadblocks time and again.

0 Comments Commercial Strategy
© 2024 MMIT

Leaning into Real-World Evidence: Lessons from the IRA

By Mike Munsell and Meg Richards

Manufacturers are continuing to wrestle with the effects of the Inflation Reduction Act (IRA) on their business plans and revenue streams. Although some of the IRA’s impacts are still uncertain, real-world evidence (RWE) is an important tool for manufacturers navigating the road ahead, as it will help them demonstrate the value and comparative effectiveness of their treatments.

Are We at a Tipping Point for Prescription Digital Therapeutics?

By Jayne Hornung

The category of treatments known as ‘digital therapeutics’ is widely misunderstood. Though the term is often conflated with ‘digital health’ tools, such as fitness trackers or meditation apps, digital therapeutics (DTx) are distinguished by their reliance on clinical evidence.
DTx products use evidence-based, clinically evaluated software to deliver medical interventions directly to patients to prevent, manage, or treat a disorder or disease. Many prescription digital therapeutics (PDTs) are software-only, while some are connected to wearable devices, and others are paired with traditional treatments.

© 2024 MMIT

Why Pharma Should Prioritize the Patient Journey: A Survivor’s Story

By Carolyn Zele

Many years ago, I became one of the first people to be diagnosed with an ultra-rare vasculitis syndrome, a dangerous inflammation of the small blood vessels. My disease is so rare that I had a much better chance of winning the lottery, but instead, I ended up sick. The story of how I was finally diagnosed is as unlikely as my disease, but it also speaks to a few broader truths about the importance of understanding the patient journey.

© 2024 MMIT